American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the American Journal of Psychiatry has published online results from its previously reported Phase 2b clinical trial of MIN-101. MIN-101 is a novel compound with affinities for sigma2 and 5HT2A receptors but no direct activity on dopamine receptors. In this regard, MIN-101 differs from drugs currently indicated for schizophrenia, all of which directly interfere with dopamine neurotransmission by antagonizing dopamine receptors.
The manuscript, entitled "Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia," and be found online at http://www.medical-reprints.com/US-MN-AJP-Davidson.
The key finding from the publication is that MIN-101 achieved its primary outcome in the trial, demonstrating statistically significant superiority over placebo in improving negative symptoms in schizophrenia patients as measured by the pentagonal negative symptoms cluster of the Positive and Negative Syndrome Scale (PANSS). The improvement in negative symptoms was shown for both doses tested: 32 milligrams (mg): p = 0.024 effect size = 0.45, and 64 mg: p = 0.004 effect size = 0.57.
Supporting these findings were similar and concomitant improvements on several secondary outcome measures, including PANSS cluster analyses of negative symptoms, the PANSS total score, the Clinical Global Impression (CGI) and the Brief Negative Symptom Scale (BNSS). Psychosis measured by the PANSS Positive symptoms subscale remained stable during the trial, suggesting that the improvement in negative symptoms associated with MIN-101 was specific and not a pseudo-effect secondary to improvements in psychosis.
MIN-101 also demonstrated good tolerability, with no weight gain or other metabolic abnormalities, no clinically significant changes in vital signs, routine laboratory values, sedation and extra-pyramidal symptoms (EPS). The lack of observed adverse effects associated with MIN-101 treatment as compared to placebo helped to preserve the blinding of the trial, further supporting the validity and specificity of the improvement observed in negative symptoms.
"Negative symptoms, which tend to persist even after psychosis improves, are the main impediment to social reintegration of schizophrenia patients," said Dr. Philip D. Harvey, Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami Miller School of Medicine and an expert in the rehabilitation of schizophrenia patients. "No drugs in the U.S. are currently indicated for negative symptoms in schizophrenia, and a drug with specific effects on negative symptoms has a real chance to improve the day-to-day social and vocational functioning of patients affected by this disease."
"The findings published in the American Journal of Psychiatry are noteworthy in that MIN-101 was shown to improve negative symptoms without blocking dopamine receptors, unlike other drugs indicated for schizophrenia," said Dr. Harvey. "As such, it may be better tolerated by patients and may improve drug adherence, which is particularly problematic in treating schizophrenia." Dr. Harvey was not involved in the design or the conduct of the Phase 2b trial with MIN-101.
"The publication of these data by a prestigious journal like the American Journal of Psychiatry is important for Minerva because it reflects a peer-reviewed recognition by the scientific and medical community of a new and innovative potential approach to alleviating the most debilitating symptoms in patients suffering from schizophrenia," said Dr. Remy Luthringer, president and chief executive officer of Minerva.
Following a recent "end-of-Phase 2" meeting with the U.S. Food and Drug Administration (FDA), Minerva expects to initiate a pivotal Phase 3 trial with MIN-101 to treat negative symptoms in schizophrenia in the second half of 2017.
About the American Journal of Psychiatry
The American Journal of Psychiatry is the official journal of the American Psychiatric Association (APA), the oldest medical association in the country, founded in 1844. It is published monthly and is focused on a broad spectrum of issues and advances in the diagnosis and treatment of mental illness. The APA is the largest psychiatric association in the world with more than 37,000 physician members specializing in the diagnosis, treatment, prevention and research of mental illness.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to: the timing and results of future clinical milestones with MIN-101, including the planned Phase 3 trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize MIN-101; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of MIN-101, if any, will be consistent with the results of past clinical trials; whether MIN-101 will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Glatfelter’s Composite Fibers Business Unit Announces 7% Price Increase23.10.2018 16:37 | Pressemelding
GERNSBACH, Germany, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Glatfelter (NYSE: GLT) announced today its Composite Fibers Business Unit will increase prices by 7% for all its products, effective November 19, 2018. The decision is a direct result of substantial and ongoing global price increases for key raw materials including pulp, synthetic fibers, viscose and other chemicals. Furthermore, the Company does not see any near-term relief from this input cost inflation. Escalating energy and transportation costs further compound the inflationary situation. “Glatfelter has made extensive efforts to reduce costs and increase efficiency,” said Martin Rapp, Senior Vice President and Business Unit President, Composite Fibers. “However, these initiatives alone are not enough to offset the impact of the external pressures. Therefore, we are implementing price adjustments to ensure our continued ability to supply best-in-class products, innovation and service.” About Glatfelter Glatfelter is a leading gl
Elite Capital & Co. Limited Awarded the “Best Project Management & Finance Company UK 2108” by Global Banking & Finance Review23.10.2018 16:10 | Pressemelding
LONDON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Mr. George Matharu, President of Elite Capital & Co. Limited (ECC), announced today that the success of being in the Global Banking & Finance Review Magazine’s 2018 Awards List was the result of enormous effort and teamwork within the company since it was founded in 2012. These Awards were established to reward excellence and recognize best practice and innovation across the Worldwide business community. Global Banking & Finance Review celebrate those who have attained the peak of achievement in terms of distinction and market influence. The list mirrors the nominations, suggestions and contributions of the readership and analyses new trends to uncover the best and the brightest pioneers in business today. This is recognition of ECC’s drive to design solutions for clients after they have exhausted traditional funding sources and methods. Elite Capital & Co. Limited is a private limited company that provides project related services including Ma
Aryaka Announces Expanded Cloud Offerings with Oracle FastConnect23.10.2018 15:00 | Pressemelding
Global enterprises can combine fast deployment, application performance, and security in a fully-managed service with direct connections to Oracle Cloud Infrastructure SAN MATEO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aryaka®, a leading global SD-WAN provider and Silver level member of Oracle PartnerNetwork (OPN), today announced it will offer dedicated and private access to the Oracle Cloud through Oracle Cloud Infrastructure FastConnect. With Aryaka’s SD-WAN as a Service and Oracle Cloud Infrastructure FastConnect, enterprises can now access their applications in the Oracle Cloud through private connections facilitated by Aryaka. Using Aryaka’s software-defined private network results in higher reliability, faster application performance, lower latencies, and higher security than typical connections over MPLS or the public Internet. Support for Oracle Cloud Infrastructure FastConnect is an integral part of Aryaka’s SD-WAN for Multi-Cloud solution which allows customers to connect
Compuware and CollabNet VersionOne Announce Integration of ISPW and Continuum23.10.2018 15:00 | Pressemelding
Partnership Enables Value Stream Management with Unified View of Cross-Platform Development and Deployment Application Development and Delivery Professionals are under pressure to track the progress of code deliverables across the DevOps lifecycle based on their value to the business. Large enterprises are additionally seeking increased visibility and control over agile development work across all platforms—from inception to delivery. The integration of ISPW, Compuware’s DevOps-enabled source code management solution for the mainframe, and CollabNet VersionOne’s Continuum release delivery platform, will serve this customer need. LAS VEGAS, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Compuware and CollabNet VersionOne today announced the completed integration of their respective products, ISPW and Continuum. The companies previously announced they were partnering to help large enterprises unify their Value Stream Management (VSM) by incorporating their critical mainframe software development acti
Hitachi Vantara Completes REAN Cloud Acquisition23.10.2018 15:00 | Pressemelding
Deal Strengthens Hitachi Vantara’s Ability To Accelerate Customers’ Digital Transformation Journeys SANTA CLARA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE: 6501), today announced the completion of its acquisition of REAN Cloud LLC, a global cloud systems integrator, managed services provider and solutions developer of cloud-native applications across big data, machine learning and emerging internet of things (IoT) spaces. Through this acquisition, Hitachi Vantara gains critical capabilities and industry-leading expertise in cloud migration and modernization, instantly elevating its cloud offering portfolio and managed services capabilities. Directly complementing the strength of its Hitachi Enterprise Cloud (HEC) and on-premises deployments, Hitachi Vantara’s solutions offer unified cloud management for workloads across public, private and hybrid cloud environments. By combining REAN Cloud’s expertise in public cloud and
Must Read Whitepaper, ‘Making Money With Network Slicing’, Hits The Shelves23.10.2018 10:00 | Pressemelding
Network Slicing Leader Cloudstreet Showcases the Vast Opportunities of this Promising New Mobile Business Model Espoo, Finland & Berlin, Germany, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cloudstreet, ‘The Network Slicing Company’, is pleased to announce the publication of its most recent industry whitepaper, “Making Money with Network Slicing”. A business-forward take on the practice, the paper puts slicing at the very center of the mobile industry’s transition now underway. With a focus on practical, market-ready models, the authors unravel the misconceptions about Network Slicing, exploring its potential to disrupt the cultural and business logjams that have hampered growth. Less about technology than a new way of doing business, Network Slicing has quickly risen from a mere buzzword to a budget line item, as mobile operators retool for the opportunities to come “Inherently disruptive, it will create new business ecosystems to support unique and evolving demands that touch quite literally e
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom